EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

R Moretto, D Rossini, Mariam Grazia Polito, Carlotta Antoniotti, Rossana Intini, Veronica Conca, Paola Andena, Martina Carullo, Lisa Salvatore, Marco Maria Germani, Francesca Bergamo, Alessandro Passardi und 8 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115470 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von R Moretto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Bevacizumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsBevacizumabHumansLeucovorinFluorouracilCamptothecinFemaleMaleOrganoplatinum CompoundsMiddle AgedPrognosisAgedAdultClinical Trials, Phase III as TopicIrinotecanNeoplasm Metastasis

Stichwörter der Autor:innen

FOLFOXIRI/bevacizumabMetastatic colorectal cancerRelative dose intensity

Substanzen

LeucovorinFluorouracilBevacizumabCamptothecinOrganoplatinum CompoundsIrinotecan

Autor:innen und Institutionen

  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Department of Experi…
  • Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy.
  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Zitieren

APA

Moretto, R., Rossini, D., Polito, M. G., Antoniotti, C., Intini, R., Conca, V., Andena, P., Carullo, M., Salvatore, L., Germani, M. M., Bergamo, F., Passardi, A., Ciracì, P., Tamburini, E., Boccaccio, C., Zaniboni, A., Masi, G., Pietrantonio, F., Lonardi, S., & Cremolini, C. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115470

Vancouver

Moretto R, Rossini D, Polito MG, Antoniotti C, Intini R, Conca V, et al. The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115470

BibTeX
@article{Moretto2025,
  author = {Moretto, R and Rossini, D and Polito, Mariam Grazia and Antoniotti, Carlotta and Intini, Rossana and Conca, Veronica and Andena, Paola and Carullo, Martina and Salvatore, Lisa and Germani, Marco Maria and Bergamo, Francesca and Passardi, Alessandro and Ciracì, Paolo and Tamburini, Emiliano and Boccaccio, Chiara and Zaniboni, Alberto and Masi, Gianluca and Pietrantonio, Filippo and Lonardi, Sara and Cremolini, C},
  title = {The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115470}
}
Kostenlos starten →